FDA asks for more information on Titan's opioid-addiction drug

05/2/2013 | Reuters

The FDA turned down a regulatory application for Probuphine, Titan Pharmaceuticals' experimental drug for opioid addiction, and asked the firm to submit additional data on the drug's efficacy. Probuphine is a long-acting version of buprenorphine, which is being marketed as Subutex and Suboxone. Titan said it was "extremely surprised and disappointed."

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY